<DOC>
	<DOCNO>NCT00555919</DOCNO>
	<brief_summary>Randomized phase II study investigate efficacy , safety tolerability ZK 230211 ( 100 mg vs. 25 mg ) second-line endocrine therapy postmenopausal woman hormone receptor-positive metastatic breast cancer.Once cancer spread beyond lymph node area e.g . skin , soft tissue , lung , liver call metastatic breast cancer . Patients diagnose metastatic breast cancer progress since previous cancer treatment remove completely surgery eligible treat within trial.Treatment new drug call Progesterone Receptor Antagonist ZK 230211 ( ZK PRA ) target progesterone receptor may express breast cancer tumour cell . Therefore patient progesterone receptor tumour cell include study.Progesterone receptor antagonist ( include onapristone ) already show efficacy postmenopausal woman advance breast cancer ( Klijn et al . 2000 ) . This phase II study investigates efficacy ( proof concept ) , safety tolerability ZK PRA two dose level ( 25 mg 100 mg ) initiate pivotal phase III trial .</brief_summary>
	<brief_title>ZK 230211 Postmenopausal Woman With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Postmenopausal woman define : age &gt; /= 50 year amenorrhea least 12 month age &lt; 50 year 6 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) level within postmenopausal range ( &gt; 40 mIU/ml ) undergone bilateral oophorectomy Histologically cytologically confirm breast cancer Metastatic breast cancer ( Stage IV accord UICC Union Internationale Contre Cancer criterion , Version 6 ) Progesterone receptorpositive tumor Patients must consider candidate endocrine therapy ( therapy breast cancer require ) Disease progression firstline endocrine therapy advance breast cancer ( i.e . tumor remission stabilization last least 3 month endocrine therapy ) At least one measurable nonmeasurable tumor lesion ( accord RECIST criterion ) WHO Performance status 1 Adequate function major organ system : Hematopoietic : Hemoglobin : 10 g/dL Absolute neutrophil count : 1,500/mm3 Platelet count : 100,000/mm3 Hepatic : Total bilirubin : 1.5 time upper limit normal AST/ALT : 2.5 time upper limit normal Renal : Creatinine : 1.5 time upper limit normal Gynecological : Endometrial thickness ( nonhysterectomized woman ) &lt; /= 10 mm double layer No uncontrolled concurrent illness Adequate recovery previous surgery , radiation chemotherapy Written inform consent Presence follow condition : lifethreatening metastatic visceral disease ( extensive hepatic involvement ) metastases central nervous system ( CNS ) pulmonary lymphangitic metastasis involve 50 % lung More one prior endocrine treatment advance breast cancer Previous combination endocrine treatment type treatment ( except chemotherapy ) , previous sequential endocrine treatment ( disease progression treatment ) permit trial . Patients breast cancer HER2 positive unknown HER2 status eligible . Malignancies history prior malignancy carcinoma situ cervix uterus , basal squamous cell carcinoma skin Intake CYP3A4 inhibitor less 2 week start study treatment A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 millisecond ( m ) A history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) The use concomitant medication prolong QT/QTc interval Other investigational drug therapy less 4 week least 5 halflives start study treatment ( le 4 week faslodex le 2 week endocrine therapy ) Expectation patient able complete least 3 month therapy Unwillingness inability comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Metastatic breast cancer stage IV</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>mBC</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>Hormone receptor positive breast cancer</keyword>
</DOC>